Summary
Ceftriaxone pharmacokinetic parameters were compiled from recent publications. The subjects (27 female, 93 male) were from 1 day to 92 years old and appeared to have normal renal and hepatic function. In 1- to 8-day-old neonates, the half-life averaged 19 hours; it declined to 6.3 hours in 1- to 6-year-old subjects and then increased gradually throughout the remainder of the life-span to 14 hours in 75- to 92-year-old subjects. The age-associated changes in half-life appeared to result from changes in systemic clearance. The fraction of the dose eliminated renally averaged 70% in neonates and declined throughout childhood to 40 to 60% in adults, in whom it was age invariant. No clinically significant differences between males and females were detected in ceftriaxone kinetic parameter values. Plasma protein binding of ceftriaxone (100 mg/L) was about 70% in neonates and it increased throughout childhood to the adult value of 90 to 95%. To achieve a given free concentration of ceftriaxone, the same dosage per unit surface area can be used for children and adults, provided glomerular filtration and biliary secretion function are normal for age. Dosage should be reduced by as much as a factor of 5 in neonates less than 1 week of age and perhaps by a factor of 2 in the very old.
Similar content being viewed by others
References
Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. Journal of Pharmacology and Experimental Therapeutics 217: 681–685, 1981
Braunlich H. Kidney development: drug elimination mechanism. In Morselli PL (Ed.) Drug disposition during development, pp. 89–100, Spectrum Publications, New York, 1977
Council KA, Helwig JT (Eds). SAS/GRAPH User’s Guide, p. 15, SAS Institute Inc., Cary, North Carolina, 1981
DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine 17: 863–871, 1916
Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 28: 169–181, 1961
Gehan EA, George SL. Estimation of body surface area from height and weight. Cancer Chemotherapy Reports Part I 54: 225–235, 1970
Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clinical Pharmacokinetics 9: 545–554, 1984
Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, et al. Steady-state pharmacokinetics of Phenytoin from routinely collected patient data. Clinical Pharmacokinetics 8: 355–364, 1983
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, et al. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 61: 27–35, 1984
Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneeis R, et al. Should clearance be normalised to body surface or to lean body mass? British Journal of Clinical Pharmacology 11: 523–526, 1981
Luderer JR, Patel IH, Durkin J, Schneck DW. Age and ceftriaxone kinetics. Clinical Pharmacology and Therapeutics 35: 19–25, 1984
Martin E, Koup JR, Paravicini U, Stoeckel K. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. Journal of Pediatrics 105: 475–481, 1984
McNamara PJ, Gibaldi M, Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. European Journal of Clinical Pharmacology 25: 399–405, 1983a
McNamara PJ, Gibaldi M, Stoeckel K. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance. European Journal of Clinical Pharmacology 25: 407–412, 1983b
McNamara PJ, Stoeckel K, Ziegler WH. Pharmacokinetics of ceftriaxone following intravenous administration of a 3g dose. European Journal of Clinical Pharmacology 22: 71–75, 1982
Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–563, 1974
Niems AH. Renal elimination of drugs at various ages. In Turner P (Ed.) Clinical pharmacology and therapeutics, pp. 117–123, MacMillan Publishers, London, 1980
Patel IH, Miller K, Weinfeld R, Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy 27(Suppl. 1): 47–56, 1981a
Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrobial Agents and Chemotherapy 20: 634–641, 1981b
Peterson LR, Gerding DN. Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. Reviews of Infectious Diseases 2: 340–348, 1980
Probst P, Crevoisier C, Heizmann P, Beck H. Unpublished data on file 1981, Hoffmann-La Roche, Basel
Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27: 469–527, 1984
Schaad UB, Hayton WL, Stoeckel K. Single-dose ceftriaxone kinetics in the newborn. Clinical Pharmacology and Therapeutics 37: 522–528, 1985
Schaad UB, Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrobial Agents and Chemotherapy 21: 248–253, 1982
Schmidt-Nielsen K. Scaling: why is animal size so important? pp. 56–98, Cambridge University Press, Cambridge, 1984
Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. Journal of Pediatrics 104: 849–854, 1984
Scully BE, Kwung PF, Neu HC. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. American Journal of Medicine 77(4C): 112–116, 1984
Stoeckel K. Pharmacokinetics of ceftriaxone, a long-acting broad-spectrum cephalosporin. In Progress in therapy of bacterial infections, pp. 5–20, Excerpta Medica, Princeton, 1983
Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler W.H. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clinical Pharmacology and Therapeutics 29: 650–657, 1981
Stoeckel K, Tuerk H, Trueb V, McNamara PJ. Single-dose ceftriaxone kinetics in patients with liver insufficiency. Clinical Pharmacology and Therapeutics 36: 500–509, 1984
Trautmann KH, Haefelfinger P. Determination of Ro 13-9904 in plasma, urine and bile by means of ion-pair reversed phase chromatography. Journal of High Resolution Chromatography Communications 4: 54–59, 1981
Vestal RE. Methodological problems associated with studies of drug metabolism in the elderly. In P. Turner (Ed.) Clinical pharmacology and therapeutics, pp. 108–116, MacMillan Publishers, London, 1980
Weiss M, Sziegoleit W, Foerster W. Dependence of pharmacokinetic parameters on the body weight. International Journal of Clinical Pharmacology 15: 572–575, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hayton, W.L., Stoeckel, K. Age-Associated Changes in Ceftriaxone Pharmacokinetics. Clin-Pharmacokinet 11, 76–86 (1986). https://doi.org/10.2165/00003088-198611010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198611010-00005